ESMO: European Society for Medical Oncology

  1. There are now four European institutions contributing to the registry
  2. At the 71st World Health Assembly (WHA) in Geneva, Switzerland, ESMO, the leading professional organisation for medical oncology, delivered two statements positioning cancer as a priority on the World Health Organisation’s (WHO) global agenda.
  3. Evaluation of the combination of atezolizumab and cobimetinib in heavily pre-treated locally advanced or metastatic CRC
  4. Comparison with non–breakthrough-designated drugs reveals only faster times to approval
  5. Atezolizumab is recommended if it is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses